SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

CHICAGO — For older patients at high risk for a heart failure event who are scheduled for transcatheter aortic valve implantation (TAVI), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) ...

A diabetes drug called dapagliflozin may help prevent heart failure in people with genetic variants linked to cardiomyopathy, ...

The U.S. SGLT2 Inhibitors Market is projected to grow from USD 5.49 Billion in 2025 to USD 11.06 Billion by 2035, while ...

Sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure (HF) related to adult congenital heart disease (ACHD) and associated with reduced ...

Heart failure affects more than 64 million people worldwide and remains a leading driver of cardiovascular morbidity and mortality. Adverse cardiac ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally, sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SGLT2 inhibitors reduce the risks for adverse kidney and ...

Author: Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai ...